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results. Correlation between adefovir resistance and clinical
factors were analyzed.
Results: Totally 106 patients were tested and 45 patients (42.5%)
were adefovir resistance (table 1). There were no statistical
differences in the rising level of HBV DNA (P>0.05) and biochem-
ical breakthrough rates (P>0.05) between patients with single
mutant and combination mutants. But patients with rtA181T
mutant had lower rising level of HBV DNA (P=0.014) and higher
rate of biochemical breakthrough (P=0.023) than resistance
patients without rtA181T mutant. There was no statistical dif-
ference in resistance rate between genotype B and C patients
(P>0.05). Adefovir resistance patients are more common in
lamivudine refractory patients than in nucleoside-naïve patients
(P=0.010).
Table 1. Adefovir resistance in tested virological breakthrough patients
Mutations Cases
rtA181T 13
rtA181V 9
rtN236T 3
rtA181V/T 1
rtA181T+rtN236T 9
rtA181V+rtN236T 8
rtA181V/T+rtN236T 2
Total 45
Conclusion: RtA181T mutant may decrease the HBV DNA rising
level, but increase the possibility of biochemical breakthrough.
In adefovir treated patients underwent virological breakthrough,
adefovir resistances are more common in lamivudine refractory
patients than in nucleoside-naïve patients.
PP-119 One case report of HBV infection with HBsAg
mutation
Xiaoning Zhang*, Wenzheng Wang, Chunyan Liu.
China is a high endemic region of HBV infection and the preva-
lence of HBsAg carriers is ∼10%. As a serum marker, HBsAg is
of predominant importance for diagnosis of HBV infection. We
reported on rare case of HBV infection with negative serum
HBsAg.
The reported case was a 17 years old female student. HBV serum
marker assay 6 month ago showed positive for only HBeAg and
anti-HBc in local town hospital. Conﬁrmative test showed same
results in our hospital with different ELISA and Colloidal Gold
Kits. For exclusion of false negative results of HBsAg caused by
Hook effect, patient serum were diluted in 1:10, 1:20, 1:100 and
1:1000 for detection and results also showed negative for HBsAg.
Negative results were also get when serum samples were under-
went acid dissociation before detection and possible affection
of HBsAg-anti-HBs immune complexes was excluded. The patient
was negative for rheumatoid factor, anti-HCV and anti-HDV. The
quantitive detection of HBsAg showed 0.12 ng/ml (0.00-0.16)
and HBV DNA level was 7.2×104 copies/ml (PCR assay, Cangzhou
central hospital).
Discussion: Repeated detection showed HBV infection in this HB-
sAg negative patient and HBsAg mutation might be the cause of
the false negative result. HBV management faces the new chal-
lenge of HBV genome mutation. α- determinant group of HBsAg is
conserved in different serotype HBV and with speciﬁc conforma-
tion. α- determinant group is the epitope of HBsAg for binding of
anti-HBs and amino acid changes in this region might cause the
changes of conformation thus affecting the antigenicity of HBsAg
by hinding the combination of HBsAg and anti-HBs. This is also
one cause of false negative detection of HBsAg. Different HBsAg
detection kits may use different monoclonal antibodies to HBsAg
and may also cause the discrepancy of HBsAg detection. Many
mutations may appear in HBsAg region and 50∼70% muations may
decrease the binding of HBsAg to anti-HBs monoclonal antibodies
in different levels. Partial muations may signiﬁcantly change the
conformation and antigenicity of HBsAg. Lack of quick assays
for mutant HBsAg and the unconsciousness of the possible risk
of this kind mutation hinder the prompt diagnosis of this kind
patients. In blood donation, this may put high risk in recipients.
So selection HBsAg detection kits with high sensitivity to mutant
HBsAg is of vital important in decrease the misdetection of
mutant HBsAg. From this case, we can also conclude that HBsAg
detection alone as the screening for blood donators may bring
the high risk of blood sample contamination. More effort should
be put on the development of HBsAg detection kit which is more
sensitive in recognizing and bingding mutant HBsAg. And other
screening assays may be considered in decreasing the risk of
blood contamination.
PP-120 Viral hepatitis in Tajikistan
Abdusamad Dustov*. Gastroenterology Institute of the Academy
of Science of the Republic of Tajikistan
Viral hepatitis is a major public health problem in all parts of
the world. Infections with hepatitis B are of particular concern
since such infection in some individuals can lead to chronic liver
disease, cirrhosis of the liver, and hepatocellular carcinoma.Two-
thirds of the subjects younger than 20 years old had been
infected with hepatitis A, 56.7% of the 77 children under 5 years
old were positive for at least one hepatitis B virus marker, and
38.2% of individuals aged 5-19 years demonstrated seropositivity
for hepatitis B virus. 39% of adults from the general population
had at least one marker for hepatitis B, 8.9% of pregnant women
were seropositive for hepatitis B surface antigen, and 61.6% of
the infants aged 0-3 years living in orphanages had at least one
marker for hepatitis B. Hepatitis C is circulating in the country.
Prevention measures must include hepatitis B immunization of
infants, with an appropriately targeted immunization strategy
determined through further epidemiological studies.
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PP-121 The necroinﬂamatory activity in chronic
hepatitis C
Dana Damian*, Mircea Grigorescu, Mircea Dan Grigorescu,
Teodor Zaharie. Third Medical Clinic, Cluj Napoca, Romania
Aim: to evaluate the necroinﬂamatory index (HAI) with the Ishak
and Metavir systems and its relationshipship with the demograph-
ical, virusological, biochemical parameters and ﬁbrosis.
Methods: We studied 242 naïve patients admitted in 2003-2006
for chronic hepatitis C, diagnosed according to clinical, biological
and morphological criteria.
Results: Irrespective of the scoring system used, most patients
had mild and moderate hepatitis lesions, with a concordance
between the results of the two examinations existing throughout
the entire group (p=0.000).
The mean age of the patients increased gradually alongside the
worsening of the hepatitis lesions, with both scoring systems,
without any changes of the sex ratio. There were no signiﬁcant
associations between the viral load and the necroinﬂamatory
activity.
We found signiﬁcant associations between the necroinﬂamatory
degrees and the ﬁbrosis stages in both scoring systems (p=0.000).
The patients presenting with hepatocytolysis had more severe
hepatitis lesions, expressed through a higher mean HAI level and
a mean ﬁbrosis index than that in the patients with normal AST
or ALT, although signiﬁcant differences were only obtained for
AST (p=0.011).
Conclusions: 1. From the point of view of the necroinﬂamatory
activity we found a predominance of the mild and moderate
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forms of hepatitis, with a concordance between the evaluations
performed through the two scoring systems.
2. The severity of the necroinﬂamatory lesions progressed paral-
lel to the patients’ age.
3. Irrespective of the scoring system used, the necroinﬂamatory
activity – evaluated at different levels – correlated with the
stages of ﬁbrosis.
PP-122 Assay of HCV cross-neutralization antibodies in
sera of hepatitis C patients
Ping Zhao1, Yi-min Tong1, Zhi-hui Chen*,2, Zhong-tian Qi 1.
1Department of Microbiology, Second Military Medical
University, Shanghai, China; 2Department of Infectious
Diseases, Changhai Hospital, Second Military Medical University,
Shanghai, China
Objective: To analyze the neutralization activity against HCV of
sera from hepatitis C patients.
Methods: A eukaryotic expression plasmid encoding carboxyl
terminal-truncated HCV envelope protein 2 (E2) was transfected
into human 293T cells. Both intracellular E2 and secreted E2
protein could be detected by western blot analysis. The intracel-
lular E2 was used to assay anti-E2 antibodies in sera of hepatitis
C patients by ELISA. The full-length envelope protein expression
plasmid was transfected into 293 T cells and the reactivity of
transfectant with anti-E2 IgG positive sera were analyzed by
immunoﬂuorescence. Five strains of HCV pseudotype particle
(HCVpp) and two strains of cell cultured HCV (HCVcc) were used
to assay the neutralization activity of 12 anti-E2 positive sera
samples.
Results: ELISA showed 26 of 32 sera samples were anti-E2 IgG
positive. The intensity of intracellular green ﬂuorescence was
paralleled with anti-E2 antibodies level of the tested sera using
immunoﬂuorescence assay. For 12 sera samples with HCV RNA
positive, the virus load is negative correlated with anti-E2 an-
tibodies levels. The anti-E2 positive sera could neutralize ﬁve
strains of HCVpp and two strains of HCVcc at various degree,
and the neutralization activity was consistent with the anti-E2
antibodies levels.
Conclusion: The results suggested that cross-neutralization an-
tibodies against HCV are present in sera of hepatitis C pa-
tients, which indicated that development of vaccines that induce
broadly-reactive neutralization antibodies may be possible.
PP-123 IFN-β and λ1, the most speciﬁc IFN subtypes in
chronic hepatitis C virus infection
Yun Ling*,1,2, Xin-Hua Li 1,2, Xiao-Fei Kong1,2, Bi-Lian Yao1,2,
Qin Zhan2, De-Ming Yu1,2, Chong Huang1,2, Gen-Di Jin1,
Qi-Ming Gong1, Jie-Hong Jiang1, Dong-Hua Zhang1,2,
Zhi-Meng Lu1,2, Shen-Ying Zhang1,2, Xin-Xin Zhang1,2.
1Department of Infectious Disease, Institute of Infectious and
Respiratory diseases, Shanghai Ruijin Hospital, Shanghai
Jiaotong University; 2Chinese-French Laboratory of Life Science
and Genomics, Shanghai Ruijin Hospital, Shanghai Jiaotong
University
Background: In humans, the type I interferon (IFN) family con-
sists of 13 IFN-α subtypes, IFN-β and IFN-ω; the type III IFN family
consists of IFN-λ1, -λ2 and -λ3. The biological signiﬁcance of the
existence of various IFN subtypes is not clear. Toll-like receptors
(TLR3, 7, 8, 9) can trigger interferon IFN-α, IFN-β and IFN-λ,
which are critical for antiviral immunity.
Methods: We investigated the 21 type I and III IFN subtypes in
chronic hepatitis C virus (HCV) infection after completed IFN
treatment for more than 3 months.
Result: Following different stimulations (Poly I:C for TLR3, Cl097
for TLR7/8, CpG-A for TLR9, HSV-1, VSV), constitutive expression
of IFN subtypes is different for different therapeutic outcome.
IFN-β is the most speciﬁc subtype induced in PBMC from HCV
patients for different therapeutic outcome. IFN-α2, α5, α7, α14,
α17, λ1 and ω are also speciﬁc for different outcome.
Conclusion: Some IFN subtype expressions correlate with anti-
HCV treatment result.
PP-124 Changes of glucose and lipid metabolism in
chronic hepatitis C
Yun-ru Li *. Beijing Ditan Hospital, Beijing, China
Aims: Our aim was to evaluate the relationship between chronic
hepatitis C (CHC) and development of diabetes mellitus (DM) or
steatosis in comparison with chronic hepatitis B (CHB).
Methods: This study consisted of 192 patients, including 82 CHC
and 110 CHB. The histological activity and ﬁbrosis and steato-
sis in liver biopsy specimens were assessed in every patients.
The serum parameters including alanine aminotransferase (ALT),
total cholesterol (CHO), triglyceride (TG) levels and fasting
plasmatic glucose were tested.
Results: The prevalence of DM in the CHC and CHB groups was
14.3%, 6.6%, respectively (CHC vs CHB, P<0.005), Steatosis was
detected in 39 out of 82 specimens (47.6%) and in 33 out of 110
CHB (28.2%) (CHC vs CHB, P<0.005), The ALT levels and the HCV
RNA load is higher in CHC with steatosis than that in in CHC
without steatosis, The triglyceride and cholesterol levels were
signiﬁcantly lower in CHC (with and without steatosis)than that
in CHB.
Conclusions: CHC patients showed a higher prevalence of DM
and steatosis than CHB patients. Lipid metabolism inﬂuences the
replication of HCV and liver injury.
PP-125 Clinical analysis of chronic hepatitis C patients
Xiaogang Xiang*,1,2, Zhixia Dong1, Qing Xie1, Jin Zhong2,
Simin Guo1, Hui Wang1, Huijuan Zhou1, Wei Cai 1, Yumin Xu1.
1Department of Infectious Disease, Ruijin Hospital, School of
Medicine, Shanghai Jiaotong University; 2Institut Pasteur of
Shanghai,Chinese Academy of Sciences, Unit of Viral Hepatitis
Objective: To investigate the modes of transmission and treat-
ment outcome in chronic hepatitis C patients.
Methods: we analyzed the clinical data of 110 patients diagnosed
as chronic hepatitis C, and recorded the modes of transmission,
clinical manifestation and the feature of laboratory examination.
We long-term followed up the patients during therapy.
Result: 35.5% of the patients was found on blood or blood prod-
ucts transfusion, 44 patients on surgery and trauma operation
(40%). The rate of HCV genotype 1b and 2a is 50.9% and 16.4%
respectively. The rate of viral load at 10c and 106 IU/ml is 27.3%
and 38.2% respectively. Obvious clinic presentation is observed
in 20.9% of patients, and 79.1% does not have obvious hepatitis
symptom and physical sign. Total SVR rate is 64.9%, genotype 1
is 54.3%, non-1 is up to 83.3%. Fever, fatigue and the decreasing
of WBC and neutrophilic granulocyte are the predominate side
effects during therapy. SVR rate is correlated with HCV genotype,
age and viral load, whereas there is no relation to ALT level.
Conclusion: The predominant modes of transmission is blood
transfusion or the using of blood products. However, surgery
and trauma operation should be paid more attention, especially
traditional Chinese medicine acupuncture. Coinfection with HBV
accounts for a certain proportion. The most common genotypes
are 1b and 2a. There is no obvious hepatitis symptom and phys-
ical sign. The impact factors on SVR are predominately HCV
genotype, RNA level and age, whereas the serum ALT level is not
signiﬁcant impact factor.
